Improvements in survival and cancer-related symptoms must be weighed up against treatment-related adverse effects and financial burden
Annual expenditure on anticancer drugs by the Pharmaceutical Benefits Scheme (PBS) has risen from $65 million in 1999–00 to $466 million in 2011–12 — an average annual increase of 19%.1 This is more than double Australia’s average annual increase in health expenditure of 8% over the same period.2 New techniques in radiation oncology and surgical oncology have also increased expenditure on cancer. It has never been more important to assess the value of new cancer treatments, weighing up the balance between benefits, harms and costs. In oncology, clinical benefit is defined by improvements in survival and cancer-related symptoms, and must be traded off against treatment-related adverse effects and financial burden. In Australia, evaluation of the trade-offs for new anticancer drugs has been predominantly a matter of health care policy, and determined by the Pharmaceutical Benefits Advisory Committee (PBAC).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Karikios DJ, Schofield D, Salkeld G, et al. Rising cost of anticancer drugs in Australia. Intern Med J 2014; 44: 458-463.
- 2. Australian Institute of Health and Welfare 2012. Health expenditure Australia 2010–11 (Cat. No. HWE 56; Health and Welfare Expenditure Series No. 47). Canberra: AIHW.
- 3. Weeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367: 1616-1625.
- 4. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015; 33: 2563-2577.
- 5. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
- 6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
- 7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
No relevant disclosures.